ProQR Therapeutics (PRQR) to Release Earnings on Wednesday

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) is expected to post its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect ProQR Therapeutics to post earnings of ($0.10) per share and revenue of $6.22 million for the quarter.

ProQR Therapeutics Stock Down 1.5 %

NASDAQ:PRQR traded down $0.03 on Friday, reaching $1.91. 379,946 shares of the company's stock traded hands, compared to its average volume of 348,112. The stock has a 50-day simple moving average of $2.34 and a 200-day simple moving average of $2.63. The firm has a market cap of $156.01 million, a PE ratio of -5.97 and a beta of 0.24. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PRQR. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Oppenheimer began coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an "outperform" rating and a $15.00 price objective for the company. Chardan Capital restated a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com lowered ProQR Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 28th. Finally, JMP Securities restated a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ProQR Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $8.83.

Remove Ads

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).